Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00615615
Previous Study | Return to List | Next Study

Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00615615
Recruitment Status : Completed
First Posted : February 14, 2008
Last Update Posted : September 17, 2013
Sponsor:
Information provided by:
UCB Pharma

Brief Summary:
Double-blind, randomized, placebo-controlled, multi-center clinical trial conducted to evaluate levetiracetam as adjunctive therapy in children (4-16 years) with refractory partial onset seizures.

Condition or disease Intervention/treatment Phase
Epilepsy Drug: Levetiracetam Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 216 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures: A 28-Week Double-Blind, Placebo-Controlled Multi-center Trial
Study Start Date : September 1999
Actual Primary Completion Date : March 2003
Actual Study Completion Date : March 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Seizures




Primary Outcome Measures :
  1. Partial onset seizure frequency per week during the treatment period. [ Time Frame: collection of seizure count throughout the whole study (baseline and treatment periods) ]

Secondary Outcome Measures :
  1. Safety [ Time Frame: Collection of safety data throughout the whole study period ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   4 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosis of epilepsy with uncontrolled partial onset seizures, whether or not secondarily generalized, and the diagnosis was >= 6 months before the Selection Visit;
  • epilepsy was classifiable according to the ILAE Classification;
  • >= 4 partial onset seizures during the 4 weeks preceding the Selection Visit and were required to have >= 4 partial onset seizures during each 4-week interval of the Baseline Period to qualify for randomization;
  • unsatisfactory current AED treatment in terms of efficacy and/or safety;
  • stable AED treatment consisting of no more than two AEDs.

Exclusion Criteria:

  • treatable seizure etiology;
  • epilepsy secondary to a progressive cerebral disease or any other progressively neurodegenerative disease, including Rasmussen and Landau-Kleffner diseases;
  • history of status epilepticus which required hospitalization during 3 months prior to the Selection Visit;
  • history of or the presence of pseudo seizures;
  • current diagnosis of Lennox-Gastaut syndrome.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00615615


Sponsors and Collaborators
UCB Pharma
Investigators
Layout table for investigator information
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Study Director, UCB
ClinicalTrials.gov Identifier: NCT00615615    
Other Study ID Numbers: N159
First Posted: February 14, 2008    Key Record Dates
Last Update Posted: September 17, 2013
Last Verified: September 2009
Keywords provided by UCB Pharma:
Levetiracetam
Keppra
Additional relevant MeSH terms:
Layout table for MeSH terms
Seizures
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Levetiracetam
Anticonvulsants
Nootropic Agents